Biology Blamed for Later-Stage Breast Cancer in Black Women

by U.S. Medicine

March 9, 2015

SAN DIEGO – African-American women present with more aggressive breast tumors and at later stages than white women. Many factors have been proposed to explain these findings, including socioeconomic status, cultural beliefs and access to medical care.

A new military study, however, suggests that biology rather than socioeconomic factors may be the most important determinant in African-American women presenting with breast cancer at later stages and with more hormone-receptor negative tumors.

The study, published recently in the Annals of Surgical Oncology, sought to determine if stage at presentation would be equivalent in the Military Health System, which provides equal access to care and equivalent screening.1

To determine that, researchers from the Naval Medical Center San Diego (NMCSD) and the Uniformed Services University in Bethesda, MD, queried the NMCSD tumor registry from 2007 to 2012, considering eligible all those diagnosed and treated for breast cancer during the time period. Distribution of tumor stage — early vs. advanced — between racial groups was compared by age, treatment and receptor status.

Of the 624 participants, 88% had early-stage breast cancer (0–II), and 12 % presented with advanced stage (III or IV). Racial differences in distribution were significant among African-American and Hispanic women for early vs. advanced presentation, although no racial disparity was seen in screening patterns among women.

“In a military health system with equal access to care and standard screening recommendations, screening patterns did not vary with race but did vary with stage and active duty status,” according to the authors, who said that biology appeared to play the biggest role in the different breast cancer stages discovered during screening.

1 Oseni TO, Soballe PW. Breast cancer screening patterns among military beneficiaries: racial variations in screening eliminated in an equal-access model. Ann Surg Oncol. 2014 Oct;21(10):3336-41. doi: 10.1245/s10434-014-3961-6. Epub 2014 Aug 5. PubMed PMID: 25092162.

Breast Cancer Res Treat. 2015 Jan;149(1):191-8. doi: 10.1007/s10549-014-3213-2. Epub 2014 Nov 27.


Comments are closed here.


Related Articles

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

Oncology

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article

Oncology

Military Risks for Ocular Surface Squamous Neoplasia

MIAMI—While a variety of risk factors have been evaluated in ocular surface squamous neoplasia, few studies have assessed risk factors specific to the armed forces veteran population. A report in the journal Eye and Vision... View Article

Oncology

Antibiotics Appear to Inhibit Tumor Activity in CTCL

AARHUS, DENMARK—Do CD4 T cell responses to  Staphylococcus aureus inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma? A prospective study in the journal Blood examined that question, exploring the... View Article

Oncology

Lower Dose Cisplatin Preferable in Squamous Cell Carcinoma

PHILADELPHIA—Chemoradiotherapy is commonly used for nonoperative treatment of locally advanced head and neck squamous cell carcinoma. The issue, according to a recent study, is that the standard dose of 100 mg/m2 cisplatin every three weeks is... View Article

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up